Form 483

Revance Therapeutics, Inc. Form 483, 2025-02-27

FDA issued a Form 483 to Revance Therapeutics, Inc. on 2025-02-27 with 1 public-safe observation.

483· Form 483 issuedHuman Drugs1 observation

Revance Therapeutics, Inc. · Newark, United States · Issued February 27, 2025

Overview

  • 1 public-safe observation is available for this inspection.
  • 1 structured CFR citation is represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

27 Feb 2025
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Linda Thai, Philip F Istafanos

Inspected site

RTRevance Therapeutics, Inc.Newark, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 1 observation

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere